Can NeuroOne Medical Technologies (NASDAQ:NMTC) Lead the Shift from Science Fiction to Evidence-Based Science

“Best Actions in Neuroscience”

Massive $13.6 billion market for neurostimulation devices. NeuroOne Medical Technologies (NASDAQ:NMTC) needs attention.

Today, a huge $13.6 billion neurostimulation device market is growing for the ongoing study of the brain’s vast networks of neural connections. (1) The diagnostic electrode technology currently used to detect neurological disorders is the same as that developed in the 1960s. (2) This is where NeuroOne Medical Technologies (NASDAQ: NMTC) comes in.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a development-stage company committed to providing minimally invasive, high-definition solutions for EEG recording, brain stimulation and ablation solutions for patients with epilepsy, Parkinson’s disease, dystonia, essential tremor, chronic pain due to failed back surgery and other related issues. neurological disorders that can improve patient outcomes and reduce procedural costs.

Mayo Clinic began testing NeuroOne’s technology in preclinical models and clinical research in 2015 and is currently a major shareholder. (3) The NeuroOne Evo range of electrodes is complementary to Zimmer Biomet’s ROSA ONE Brain platform used in minimally invasive neurosurgery. (3) NeuroOne has received FDA clearance for its Evo Cortical and sEEG electrodes. (4) This innovative company is behind the scenes bringing what might once be considered sci-fi inspired technologies to the brink of creation or they already have it in development. And thanks to NeuroOne’s strategic partnerships, they expect their technologies to be widely adopted in the near future. Click HERE to learn more about why the future of neuroscience relies on this thin-film electrode technology

Other companies in the NeuroOne Medical Tech space include: ENDRA Life Sciences (NASDAQ:NDRA), Second Sight Medical (NASDAQ:EYES), Bluejay Diagnostics (NASDAQ:BJDX), Motus GI Hldgs (NASDAQ:MOTS) and Tivic Health Systems (NASDAQ: TIVC). It might be worth investigating if Tesla (NASDAQ:TSLA) co-founder Elon Musk’s company, Neuralink, and NeuroOne Medical Technologies (NASDAQ:NMTC) have anything in common. As always, do your due diligence.

Sources:

Source 1: https://www.gminsights.com/pressrelease/neurostimulation-devices-market-size

Source 2: https://n1mtc.com/investorsSource

Source 3: https://seekingalpha.com/article/4470806-neuroone-nmtc-stock-thin-film-electrodes-neurological-conditions

Source 4: https://www.mpo-mag.com/contents/view_breaking-news/2021-12-08/fda-clears-neuroone-medical-technologies-evo-seeg-electrode/

Additional Sources:

https://www.mayoclinic.org/about-mayo-clinic

https://www.yahoo.com/now/neuroone-medical-technologies-corporation-announces-130000582.html

https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.01118

Disclaimer: WallStreetPR merely distributes content provided to us by Bullzeyemedia LLC and is not responsible for the production of such content. WallStreetPR is not operated by a licensed broker, broker or registered investment adviser. It should be expressly understood that in no way does the information published here represent a recommendation to buy or sell a security. Our reports/press releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in stocks featured on our site or in emails unless you can afford to lose your entire investment. The information made available by BullzeyeMedia LLC is not intended to be, nor does it constitute investment advice or recommendations. Contributors can buy and sell titles before and after any particular article, report, and publication. In no event shall WALLSTREETPR be liable to any member, guest or third party for any damages of any kind arising from the use of any content or other material published or made available by WALLSTREETPR., including , without limitation, any loss of investment, loss of profits, missed opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article and related newsletters is not intended to be, nor does it constitute investment advice or recommendations. WallStreetPR.com strongly recommends that you conduct a full and independent investigation of the respective companies and consider all relevant risks. Readers are encouraged to consult the SEC’s periodic reports: Forms 10-Q, 10K, Form 8-K, Insider Reports, Forms 3, 4, 5, Schedule 13D. For certain content, Wallstreetpr.com, its authors, contributors or agents may be compensated for the preparation of research, video graphics and editorial content. As part of this content, readers, subscribers and website visitors are expected to read the full Disclaimers and Financial Disclosure Statement which can be found on our website by visiting WallStreetPR.com /Disclaimer. WallStreetPR.com was compensated $750 for advertising services on NMTC by a 3rd part of BullzeyeMedia LLC. The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor regarding forward-looking statements. Any statements that express or imply discussions regarding predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made, which involve a number of risks and uncertainties that could cause actual results or events to differ materially from those currently anticipated. . Forward-looking statements in this action can be identified by the use of words such as plans, foresee, expect, anticipate, estimate, believe, understand, or by statements indicating certain actions and quotes; can, could or could happen. Understand that there is no guarantee that past performance will be indicative of future results. Investing in microcap and growth stocks is highly speculative and involves an extremely high degree of risk. It is possible that an investor’s investment could be lost or depreciated due to the speculative nature of the companies featured.

Media Contact
Company Name: WallStreetPR
Contact: Ash K
E-mail: Send an email
Call: 2019725655
Country: United States
Website: https://www.wallstreetpr.com/

Source link

About Donald P. Hooten

Check Also

Best New Science Fiction Books in May 2022

Idris, who has spent decades fleeing the horrors of his past, finds himself pushed back …